Abstract |
Xanthatin, a sesquiterpene lactone purified from Xanthium strumarium L., possesses prominent anticancer activity. We found that disruption of GSK3β activity was essential for xanthatin to exert its anticancer properties in non-small cell lung cancer (NSCLC), concurrent with preferable suppression of constitutive activation of STAT3. Interestingly, inactivation of the two signals are two mutually exclusive events in xanthatin-induced cell death. Moreover, we surprisingly found that exposure of xanthatin failed to trigger the presumable side effect of canonical Wnt/β- Catenin followed by GSK3β inactivation. We further observed that the downregulation of STAT3 was required for xanthatin to fine-tune the risk. Thus, the discovery of xanthatin, which has ability to simultaneously orchestrate two independent signaling cascades, may have important implications for screening promising drugs in cancer therapies.
|
Authors | Li Tao, Fangtian Fan, Yuping Liu, Weidong Li, Lei Zhang, Junshan Ruan, Cunsi Shen, Xiaobo Sheng, Zhijie Zhu, Aiyun Wang, Wenxing Chen, Shile Huang, Yin Lu |
Journal | PloS one
(PLoS One)
Vol. 8
Issue 11
Pg. e81945
( 2013)
ISSN: 1932-6203 [Electronic] United States |
PMID | 24312384
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents
- Furans
- STAT3 Transcription Factor
- STAT3 protein, human
- beta Catenin
- xanthatin
- GSK3B protein, human
- Glycogen Synthase Kinase 3 beta
- Glycogen Synthase Kinase 3
|
Topics |
- Antineoplastic Agents
(pharmacology, therapeutic use)
- Apoptosis
- Carcinoma, Non-Small-Cell Lung
(enzymology, metabolism, pathology)
- Cell Line, Tumor
- Cell Proliferation
- Furans
(pharmacology, therapeutic use)
- Glycogen Synthase Kinase 3
(antagonists & inhibitors, metabolism)
- Glycogen Synthase Kinase 3 beta
- Humans
- Lung Neoplasms
(enzymology, metabolism, pathology)
- RNA Processing, Post-Transcriptional
- STAT3 Transcription Factor
(antagonists & inhibitors, metabolism)
- beta Catenin
(metabolism)
|